Aleksandra Gentry-Maharaj

List of Publications by Year
in descending order

119 papers	10,675 citations	46984 47 h-index	33869 99 g-index
124 all docs	124 docs citations	124 times ranked	15827 citing authors

#	Article	IF	Citations
1	Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 110-118.	1.1	2
2	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Journal of Medical Genetics, 2022, 59, 632-643.	1.5	33
3	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
4	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	2.1	15
5	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
6	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	3.0	8
7	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancers, 2021, 13, 858.	1.7	6
8	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. Trials, 2021, 22, 173.	0.7	4
9	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2021, 397, 2182-2193.	6.3	313
10	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trialsâ€"an ovarian cancer exemplar. Trials, 2021, 22, 88.	0.7	7
11	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. American Journal of Obstetrics and Gynecology, 2020, 222, 56.e1-56.e17.	0.7	25
12	Serial endometrial thickness and risk of nonâ€endometrial hormoneâ€dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening. Ultrasound in Obstetrics and Gynecology, 2020, 56, 267-275.	0.9	2
13	Current and future approaches to screening for endometrial cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 79-97.	1.4	35
14	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers, 2020, 12, 1931.	1.7	18
15	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 caseâ€"control studies. European Journal of Epidemiology, 2020, 35, 1025-1042.	2.5	2
16	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers, 2020, 12, 1241.	1.7	19
17	Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 2020, 31, 1240-1250.	0.6	85
18	Ovarian cancer symptoms, routes to diagnosis and survival â€" Population cohort study in the â€˜no screenâ€™ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology, 2020, 158, 316-322.	0.6	29

#	Article	IF	Citations
19	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
20	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
21	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. Diagnostics, 2020, 10, 89.	1.3	5
22	Improved early detection of ovarian cancer using longitudinal multimarker models. British Journal of Cancer, 2020, 122, 847-856.	2.9	60
23	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. BMC Gastroenterology, 2020, 20, 104.	0.8	5
24	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. British Journal of Cancer, 2019, 121, 483-489.	2.9	32
25	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prevention Research, 2019, 12, 391-400.	0.7	17
26	Colorectal cancer ascertainment through cancer registries, hospital episode statistics, and self-reporting compared to confirmation by clinician: A cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancer Epidemiology, 2019, 58, 167-174.	0.8	7
27	The role of transvaginal ultrasound in screening for ovarian cancer. Climacteric, 2018, 21, 221-226.	1.1	16
28	Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2018, 18, 409.	1.2	0
29	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. American Journal of Epidemiology, 2018, 187, 366-377.	1.6	8
30	Sonographers' self-reported visualization of normal postmenopausal ovaries on transvaginal ultrasound is not reliable: results of expert review of archived images from UKCTOCS. Ultrasound in Obstetrics and Gynecology, 2018, 51, 401-408.	0.9	10
31	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	1.5	38
32	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	1.3	70
33	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. Clinical Cancer Research, 2018, 24, 4726-4733.	3.2	39
34	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
35	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). F1000Research, 2018, 7, 1241.	0.8	2
36	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. British Journal of Cancer, 2017, 116, 501-508.	2.9	86

#	Article	IF	Citations
37	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus. Circulation, 2017, 135, 2373-2388.	1.6	304
38	Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening. Climacteric, 2017, 20, 240-247.	1.1	69
39	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
40	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	3.4	260
41	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5912-5922.	3.2	47
42	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2017, 7, e011822.	0.8	8
43	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2017, 17, 603.	1.2	11
44	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. British Journal of Cancer, 2017, 117, 666-674.	2.9	47
45	Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. International Journal of Molecular Sciences, 2017, 18, 2670.	1.8	23
46	Novel risk models for early detection and screening of ovarian cancer. Oncotarget, 2017, 8, 785-797.	0.8	13
47	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). PLoS ONE, 2016, 11, e0165539.	1.1	8
48	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics and Gynecology, 2016, 127, 828-836.	1.2	39
49	Protein Z: A putative novel biomarker for early detection of ovarian cancer. International Journal of Cancer, 2016, 138, 2984-2992.	2.3	41
50	A splicing variant of *TERT* identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal of Cancer, 2016, 139, 2646-2654.	2.3	7
51	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
52	Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in Obstetrics and Gynecology, 2016, 47, 228-235.	0.9	17
53	Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1012-1020.	1.1	21
54	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2016, 387, 945-956.	6.3	791

#	Article	IF	Citations
55	Assessment of Multifactor Gene–Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	1.1	10
56	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	0.8	20
57	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clinical Cancer Research, 2016, 22, 1734-1743.	3.2	69
58	Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clinical Cancer Research, 2015, 21, 622-631.	3.2	158
59	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
60	Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. British Journal of Cancer, 2015, 113, 268-274.	2.9	84
61	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2015, 15, 253.	1.2	9
62	Screening for Gynaecological Cancers. , 2015, , 267-281.		0
63	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Journal of Clinical Oncology, 2015, 33, 2062-2071.	0.8	166
64	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy. Menopause, 2015, 22, 384-390.	0.8	25
65	Contribution of Germline Mutations in the <i>RAD51B</i>, <i>RAD51C</i>, and <i>RAD51D</i> Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907.	0.8	266
66	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	311
67	Multiprobabilistic prediction in early medical diagnoses. Annals of Mathematics and Artificial Intelligence, 2015, 74, 203-222.	0.9	9
68	Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. Journal of Proteomics, 2015, 113, 400-402.	1.2	38
69	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer, 2014, 111, 2297-2307.	2.9	76
70	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2014, 4, e004421.	0.8	15
71	Cancer–associated autoantibodies to MUC1 and MUC4—A blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International Journal of Cancer, 2014, 134, 2180-2188.	2.3	49
72	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Medicine, 2014, 6, 47.	3.6	53

#	ARTICLE	IF	CITATIONS
73	Ovarian cancer screening—Current status, future directions. Gynecologic Oncology, 2014, 132, 490-495.	0.6	115
74	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	3.0	186
75	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	1.5	16
76	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics - Clinical Applications, 2014, 8, 982-993.	0.8	41
77	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	5.1	335
78	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
79	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
80	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes and Control, 2013, 24, 989-1004.	0.8	84
81	Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Ultrasound in Obstetrics and Gynecology, 2013, 41, 73-79.	0.9	18
82	Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. Journal of Proteome Research, 2013, 12, 1408-1418.	1.8	96
83	Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British Journal of Cancer, 2013, 108, 2045-2055.	2.9	52
84	Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in Obstetrics and Gynecology, 2013, 42, 472-477.	0.9	14
85	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1677-1686.	1.1	70
86	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	1.1	54
87	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	1.6	169
88	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
89	Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer, 2013, 109, 2875-2879.	2.9	8
90	Early detection of cancer in the general population: a blinded case–control study of p53 autoantibodies in colorectal cancer. British Journal of Cancer, 2013, 108, 107-114.	2.9	73

#	Article	IF	Citations
91	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. Journal of the National Cancer Institute, 2012, 104, 114-124.	3.0	49
92	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocrine-Related Cancer, 2012, 19, 137-147.	1.6	36
93	Screening of symptomatic women for ovarian cancer. Lancet Oncology, The, 2012, 13, e138-e139.	5.1	4
94	Risk of epithelial ovarian cancer in asymptomatic women with ultrasoundâ€detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound in Obstetrics and Gynecology, 2012, 40, 338-344.	0.9	64
95	Conformal predictors in early diagnostics of ovarian and breast cancers. Progress in Artificial Intelligence, 2012, 1, 245-257.	1.5	14
96	Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 207-219.	1.1	32
97	Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a crossâ€sectional cohort study of 10â€ƒ418 British women aged 54â€"65. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 40-50.	1.1	105
98	Screening for ovarian cancer in the general population. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 243-256.	1.4	41
99	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. Trials, 2011, 12, 61.	0.7	40
100	Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertility and Sterility, 2011, 95, 40-45.	0.5	20
101	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. Journal of Clinical Epidemiology, 2011, 64, 525-530.	2.4	30
102	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncology, The, 2011, 12, 38-48.	5.1	176
103	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. International Journal of Cancer, 2011, 128, 936-943.	2.3	49
104	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics, 2011, 20, 2263-2272.	1.4	22
105	Ovarian Cancer Screening and Mortality. JAMA - Journal of the American Medical Association, 2011, 306, 1544.	3.8	22
106	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
107	Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. Clinical Chemistry, 2010, 56, 262-271.	1.5	31
108	T1394 Serum CEACAM1 in the Preclinical Diagnosis of Pancreatic Adenocarcinoma. Gastroenterology, 2010, 138, S-553.	0.6	0

#	Article	IF	Citations
109	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Research, 2010, 20, 440-446.	2.4	740
110	Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. International Journal of Gynecological Cancer, 2010, 20, 1518-24.	1.2	11
111	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Human Molecular Genetics, 2009, 18, 2928-2928.	1.4	0
112	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	9.4	276
113	Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. British Journal of Cancer, 2009, 100, 993-1001.	2.9	24
114	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, The, 2009, 10, 327-340.	5.1	738
115	An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. PLoS ONE, 2009, 4, e8274.	1.1	291
116	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	2.3	73
117	Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. BMJ: British Medical Journal, 2008, 337, a2079-a2079.	2.4	128
118	Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clinical Chemistry, 2007, 53, 645-656.	1.5	131
119	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause, 2007, 14, 462-467.	0.8	36